Bristol-Myers Squibb Company (BMY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $58.08. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BMY = $39.61 (-31.8% from the current price, the stock appears overvalued). Analyst consensus target is BMY = $63 (+8% upside).
Valuation: BMY trades at a trailing Price-to-Earnings (P/E) of 17.1 (S&P 500 average ~25).
Financials: revenue is $48.2B, +1.5%/yr average growth. Net income is $7.1B, growing at -1.9%/yr. Net profit margin is 14.6% (healthy). Gross margin is 67.6% (-10.4 pp trend).
Balance sheet: total debt is $47.1B against $18.5B equity (Debt-to-Equity (D/E) ratio 2.55, leveraged). Current ratio is 1.26 (adequate). Debt-to-assets is 52.4%. Total assets: $90.0B.
Analyst outlook: 19 / 41 analysts rate BMY as buy (46%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 69/100 (Pass), Growth 30/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 75/100 (Pass), Future 40/100 (Partial), Income 55/100 (Partial).
